Morgan Stanley Starts Syndax Pharmaceuticals (SNDX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts SNDX Hot Sheet
Price: $13.40 -1.25%
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Morgan Stanley initiated coverage on Syndax Pharmaceuticals (NASDAQ: SNDX) with an Overweight rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Syndax Pharmaceuticals click here. For more ratings news on Syndax Pharmaceuticals click here.
Shares of Syndax Pharmaceuticals closed at $12.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Starts Yamazaki Baking Co Ltd (2212:JP) at Buy
- Citi Starts Kewpie Corp (2809:JP) at Neutral
- Morgan Stanley Downgrades BE Semiconductor (BESI:NA) (BESIY) to Equalweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
